<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>CytoCares | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-02T20:21:34+08:00</updated>
  <subtitle>为您传递细胞治疗相关行业信息与技术进展，共同促进国内免疫治疗技术发展与行业繁荣</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>单克隆抗体技术简史及经典药物</title>
    <updated>2020-11-02T18:53:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/1Iyt4bVZ-5ntEuosHp9U0g</id>
    <link href="https://mp.weixin.qq.com/s/1Iyt4bVZ-5ntEuosHp9U0g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>转座子系统在CAR-T中的应用</title>
    <updated>2020-10-29T18:50:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/iFy_tb8-eU1aBdhflM2CEQ</id>
    <link href="https://mp.weixin.qq.com/s/iFy_tb8-eU1aBdhflM2CEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-10月29日</title>
    <updated>2020-10-29T18:50:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/q-B25q1iVx_3TpKlaEKhug</id>
    <link href="https://mp.weixin.qq.com/s/q-B25q1iVx_3TpKlaEKhug" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-10月28日</title>
    <updated>2020-10-28T19:00:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/9yYeIxKc-1Mg1iBd2MReyQ</id>
    <link href="https://mp.weixin.qq.com/s/9yYeIxKc-1Mg1iBd2MReyQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>T细胞导向疗法在实体瘤的挑战和机遇</title>
    <updated>2020-10-27T18:45:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/tYA12pI7BAg5Kn_vSa1m9Q</id>
    <link href="https://mp.weixin.qq.com/s/tYA12pI7BAg5Kn_vSa1m9Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-10月27日</title>
    <updated>2020-10-27T18:45:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/KO-uWiVT0HaUbIu9zpa7Kw</id>
    <link href="https://mp.weixin.qq.com/s/KO-uWiVT0HaUbIu9zpa7Kw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>冲破层层迷障，第三代ADC已崭露头角</title>
    <updated>2020-10-26T18:55:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/z6_cXDbig8XbeESOWR3TmQ</id>
    <link href="https://mp.weixin.qq.com/s/z6_cXDbig8XbeESOWR3TmQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Nature二连发：靶向TGF-β新疗法，肿瘤治疗新曙光</title>
    <updated>2020-10-23T19:47:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-23:/s/pcJ1i68X8kqnkllwudZhBQ</id>
    <link href="https://mp.weixin.qq.com/s/pcJ1i68X8kqnkllwudZhBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CD3抗原为靶点的药物研发进展</title>
    <updated>2020-10-22T19:14:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-22:/s/BfEal6BFkFnd5LGov-yrnw</id>
    <link href="https://mp.weixin.qq.com/s/BfEal6BFkFnd5LGov-yrnw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-10月22日</title>
    <updated>2020-10-22T19:14:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-22:/s/p-eCQTdYR3-DzJvNxYlUgw</id>
    <link href="https://mp.weixin.qq.com/s/p-eCQTdYR3-DzJvNxYlUgw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>免疫检查点抑制剂的临床挑战</title>
    <updated>2020-10-16T18:30:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-16:/s/xonfydNCrZgtrbfrsSLIOw</id>
    <link href="https://mp.weixin.qq.com/s/xonfydNCrZgtrbfrsSLIOw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>下周有约|2020金秋十月第三届抗体药产业发展大会</title>
    <updated>2020-10-16T18:30:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-16:/s/xdqsrBctNVHP9ENROt8kAw</id>
    <link href="https://mp.weixin.qq.com/s/xdqsrBctNVHP9ENROt8kAw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>靶向CD47/SIRPα的抗肿瘤治疗研究进展</title>
    <updated>2020-10-15T18:47:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-15:/s/v-rRuQOe1vdNwNjCeLmtpQ</id>
    <link href="https://mp.weixin.qq.com/s/v-rRuQOe1vdNwNjCeLmtpQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-10月15日</title>
    <updated>2020-10-15T18:47:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-15:/s/v5oSVr_jpfiSax2fcwXprw</id>
    <link href="https://mp.weixin.qq.com/s/v5oSVr_jpfiSax2fcwXprw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>技术|抗体Fc功能及改造方向</title>
    <updated>2020-10-14T18:57:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-14:/s/MS8MSmfkDkMMMuJQvLNeTw</id>
    <link href="https://mp.weixin.qq.com/s/MS8MSmfkDkMMMuJQvLNeTw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-10月14日</title>
    <updated>2020-10-14T18:57:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-14:/s/m3EBy2HMbe8FIaNFLL18jA</id>
    <link href="https://mp.weixin.qq.com/s/m3EBy2HMbe8FIaNFLL18jA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>